Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCALATE: Radium-223 with Enzalutamide or Darolutamide in mCRPC
NCT04237584Phase 3Terminated
- Sponsor
- MANA RBM
- Start
- Jun 2020
- Primary completion
- Mar 2022
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of radium-223 dichloride in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by MANA RBM. Primary endpoint: Symptomatic Skeletal Event-free Survival. Started Jun 2020; status: terminated.
02
Drugs
radium-223 dichloride
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04237584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04237584.